(Q36408642)

14 August 2017

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors (English)

1 reference

14 August 2017

Lillian L Siu

1

1 reference

14 August 2017

Roberto Pili

2

1 reference

14 August 2017

Ignacio Duran

3

1 reference

14 August 2017

Wells A Messersmith

4

1 reference

14 August 2017

Eric X Chen

5

1 reference

14 August 2017

Rana Sullivan

6

1 reference

14 August 2017

Martha MacLean

7

1 reference

14 August 2017

Serina King

8

1 reference

14 August 2017

Shirley Brown

9

1 reference

14 August 2017

Gregory K Reid

10

1 reference

14 August 2017

Zuomei Li

11

1 reference

14 August 2017

Ann M Kalita

12

1 reference

14 August 2017

Eric J Laille

13

1 reference

14 August 2017

Jeffrey M Besterman

14

1 reference

14 August 2017

Robert E Martell

15

1 reference

14 August 2017

Michael A Carducci

16

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Journal of Clinical Oncology

14 August 2017

1 reference

14 August 2017

26

1 reference

14 August 2017

12

1 reference

14 August 2017

1940-1947

1 reference

Functional imaging of cancer with emphasis on molecular techniques

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Histone deacetylase inhibitors: biology and mechanism of action

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

New technologies and directed agents for applications of cancer imaging

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Prospects: histone deacetylase inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Histone acetylases and deacetylases in cell proliferation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

HDAC inhibitors: clinical update and mechanism-based potential.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501257

21 September 2018

Identifiers

DOI

10.1200/JCO.2007.14.5730

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

18421048

1 reference